CD163 Antibody (10D6)

CD163 (Cluster of Differentiation 163), also known by several other names including M130, p155, RM3/1, Ki-M8, Ber-MAC3, SM4, and GHI/61, is a type I transmembrane glycoprotein that is a member of the scavenger receptor cysteine-rich (SRCR) super family class B (1-3). CD163 is expressed specifically on the monocyte/macrophage lineage and has a theoretical molecular weight of 130-160 kDa in reducing conditions and 110 kDa in non-reducing conditions (2 - 6). CD163 is synthesized as 1076 amino acid (aa) protein consisting of a large extracellular domain (ECD) with nine SRCR domains, proline-serine-threonine rich (PST) linker domain, a transmembrane segment, and a cytoplasmic tail which has varying lengths depending on the isoform due to alternative splicing, with the short 49 aa form being the most common (1-3, 6).

One of the primary functions of CD163 is uptake of haptoglobin-hemoglobin (Hp-Hb) complexes from the liver, spleen, and bone marrow, ultimately triggering an anti-inflammatory response (3, 5, 7). CD163 also functions as an erythroblast adhesion receptor and promotes cell maturation and survival (3, 5, 7). Furthermore, CD163 functions in immune sensing of bacteria and as a receptor for tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) (3, 5, 7). As mentioned above, CD163 is expressed on cells in the monocyte/macrophage lineage and, in general, anti-inflammatory signals including glucocorticoids, interleukin (IL)-6, and IL-10 stimulate CD163 synthesis and expression while, conversely, pro-inflammatory signals such as interferon-gamma (INF-gamma), TNF-alpha, and lipopolysaccharide (LPS) downregulate CD163 (3, 5). In addition to membrane-bound form of CD163, the protein can be cleaved by metalloproteinases (MMP) and induced by LPS or phorbol myristate acetate (PMA) to release a soluble form (sCD163) into the plasma (7). Increased levels of sCD163 in the plasma and an increased number of CD163-expressing macrophages at the site of inflammation are associated with a variety of pathologies (3, 5-7). CD163/sCD163 is often increased and a suitable clinical marker for inflammatory diseases including rheumatoid arthritis (RA), Gaucher disease, chronic kidney disease, diabetes, and Crohn's disease (3, 5-7).

Alternative names for CD163 includes GHI/61, HbSR, Hemoglobin scavenger receptor, M130, macrophage-associated antigen, MM130, RM3/1, SCARI1, scavenger receptor cysteine-rich type 1 protein M130, sCD163, and soluble CD163.

References

1. Law, S. K., Micklem, K. J., Shaw, J. M., Zhang, X. P., Dong, Y., Willis, A. C., & Mason, D. Y. (1993). A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. European journal of immunology. https://doi.org/10.1002/eji.1830230940

2. Onofre, G., Kolackova, M., Jankovicova, K., & Krejsek, J. (2009). Scavenger receptor CD163 and its biological functions. Acta medica (Hradec Kralove).

3. Van Gorp, H., Delputte, P. L., & Nauwynck, H. J. (2010). Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Molecular immunology. https://doi.org/10.1016/j.molimm.2010.02.008

4. Sulahian, T. H., Hogger, P., Wahner, A. E., Wardwell, K., Goulding, N. J., Sorg, C., Droste, A., Stehling, M., Wallace, P. K., Morganelli, P. M., & Guyre, P. M. (2000). Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine. https://doi.org/10.1006/cyto.2000.0720

5. Etzerodt, A., & Moestrup, S. K. (2013). CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxidants & redox signaling. https://doi.org/10.1089/ars.2012.4834

6. Skytthe, M. K., Graversen, J. H., & Moestrup, S. K. (2020). Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases. International journal of molecular sciences, 21(15), 5497. https://doi.org/10.3390/ijms21155497

7. Moller H. J. (2012). Soluble CD163. Scandinavian journal of clinical and laboratory investigation. https://doi.org/10.3109/00365513.2011.626868

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: ICC/IF, IF/IHC, IHC-P.

Showing Publications 1 - 10 of 21. Show All 21 Publications. Collapse Publications.

Publications using NB110-59935	Applications	Species
Leader A, Grout J, Chang C et al. CITEseq analysis of non-small-cell lung cancer lesions reveals an axis of immune cell activation associated with tumor antigen load and TP53 mutations bioRxiv 2020-07-17
Blom AM, Gialeli C, Hagerling C et al. Expression of Cartilage Oligomeric Matrix Protein in colorectal cancer is an adverse prognostic factor and correlates negatively with infiltrating immune cells and PD-L1 expression Frontiers in immunology 2023-05-03 [PMID: 37207219] (IHC-P, Human) Details: Dilutin 1:200	IHC-P	Human
Ma J, Li J, He N et al. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis Journal of translational medicine 2023-02-03 [PMID: 36737759] (IHC-P, Human)	IHC-P	Human
Ma j, Li J, He N et al. Identification and validation of a novel survival prediction model based on the T cell phenotype in tumor immune microenvironment and peripheral blood for the prognosis in gastric cancer Research Square 2022-10-24 [PMID: 36737759]
Kim KH, Park J, Cho Y et al. Histamine Signaling Is Essential for Tissue Macrophage Differentiation and Suppression of Bacterial Overgrowth in the Stomach Cellular and Molecular Gastroenterology and Hepatology 2023-01-01 [PMID: 36167263]
Litta F, Papait A, Lucchetti D et al. The pathogenesis of cryptoglandular anal fistula: New insight into the immunological profile Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2022-08-02 [PMID: 35916639] (ICC/IF, Human) Details: Dilution used 1:50	ICC/IF	Human
Gatenbee C, Baker A, Schenck R Et al. Immunosuppressive niche engineering at the onset of human colorectal cancer Nat Commun 2022-04-05 [PMID: 35379804]
Horn LA, Chariou PL, Gameiro SR et al. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-beta signaling enables PD-L1-mediated tumor eradication The Journal of clinical investigation 2022-03-01 [PMID: 35230974] (IF/IHC)	IF/IHC
Cuevas VD, SimOn-Fuentes M, Orta-Zavalza E Et al. The Gene Signature of Activated M-CSF-Primed Human Monocyte-Derived Macrophages Is IL-10-Dependent Journal of innate immunity 2021-10-20 [PMID: 34670213] (IF/IHC, Human)	IF/IHC	Human
Consonni FM, Bleve A, Totaro MG et al. Heme catabolism by tumor-associated macrophages controls metastasis formation Nature immunology 2021-04-26 [PMID: 33903766] (IF/IHC, Human)	IF/IHC	Human
Xu Y, Li J, Tong B et al. Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer ESMO Open 2020-08-01 [PMID: 32830120] (IF/IHC, Human)	IF/IHC	Human
Wagner M, Reinke S, Hansel R et Al. An image dataset related to automated macrophage detection in immunostained lymphoma tissue samples Gigascience 2020-03-01 [PMID: 32161948] (IHC-P, Human)	IHC-P	Human
Esbona K, Yi Y, Saha S et al. The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients Am J Pathol. 2019-02-28 [PMID: 29429545] (IHC-P, Human)	IHC-P	Human
Li YP, Wang WZ, Chen XQ et al. Signal Transducer and Activator of Transcription 3 for the Differentiation of Hepatocellular Carcinoma from Cirrhosis Chin. Med. J. 2017-11-20 [PMID: 29133756] (Human)		Human
Lundgren S, Karnevi E, Elebro J et al. The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype J Transl Med 2017-07-03 [PMID: 28673320] (IF/IHC, Human)	IF/IHC	Human
Burgess M, Mapp S, Mazzieri R, Cheung C Increased FcRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients. Oncogene 1905-07-08 [PMID: 27748757] (ICC/IF, Human)	ICC/IF	Human
Herbst Rs, Soria Jc, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014-11-27 [PMID: 25428504] (IF/IHC)	IF/IHC
Gadd VL, Melino M, Roy S et al. Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C Liver Liver Int 2012-11-12 [PMID: 23240894] (IHC-P, Human)	IHC-P	Human
Melino M, Gadd VL, Walker GV, et al. Macrophage secretory products induce an inflammatory phenotype in hepatocytes World J Gastroenterol 2012-04-21 [PMID: 22553397] (IHC-P, Human)	IHC-P	Human
Fealey ME, Edwards WD, Miller DV, Maleszewski JJ. Unicommissural aortic valves: gross, histological, and immunohistochemical analysis of 52 cases (1978-2008). Cardiovasc Pathol. 2011-12-27 [PMID: 22206734] (IF/IHC, Human)	IF/IHC	Human
Show All 21 Publications. Collapse Publications.

Images	Ratings	Applications	Species	Date	Details
Enlarge	4 reviewed by: Verified Customer	IHC-P	Human	10/06/2015	View Summary Application Immunohistochemistry-Paraffin Sample Tested Lymph node Species Human Lot E097

Array NB110-59935

• CD163 Antibodies
• CD163 ELISA Kits
• CD163 Lysate
• CD163 Proteins
• CD163 ELISAs
• CD163 Proteins and Enzymes